English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduCAR031 study at 9.03-mo median follow up achieves disease control rate (DCR) of 91.3% and objective response rate (ORR) of 56.5% for patients across all dose levels (DLs) and ORR of 75.0% at DL4
Tag: ASCO 2024
ASCO: New ‘Armored’ CAR produces significant responses in patients whose cancers don’t respond to current CAR T cell therapies
A new “armored” form of CAR T cell therapy may be able to help patients with non-Hodgkin lymphoma whose cancers do not respond to currently available CAR T cell therapies. The Phase I clinical trial was presented at the 2024 ASCO Annual Meeting.
Clinical trials show promise in treating central nervous system lymphoma, breast cancer, and glioblastoma
Dana-Farber Cancer Institute researchers are leading 3 separate studies with encouraging results in treating patients with central nervous system (CNS) lymphoma, breast cancer, and glioblastoma. These findings are among more than 80 studies presented at ASCO that are led by Dana-Farber-affiliated researchers.
Study Reveals Worse Clinical Outcomes in Breast Cancer Patients Who Reported Higher Pain and Stress
Secondary analyses of a phase 3 clinical trial have revealed that breast cancer patients who reported high levels of pain and stress were more likely than their study peers to experience worse invasive disease-free survival (iDFS) and worse overall survival (OS).
Study Shows Polygenic Risk Score (PGS) Could Predict Breast Cancer Survival Outcomes
Data from a large prospective cohort study reveal that a polygenic risk score has the potential to predict survival outcomes in patients with breast cancer.
Promising New Treatment for Patients with HR+ HER-2 Negative Metastatic Breast Cancer
New research from Yale Cancer Center reveals first-of-its-kind data from a phase I study in patients with hormone receptor positive HER2-negative metastatic breast cancer. The results, which assess the safety and efficacy of a treatment known as PF-07248144, offer new hope for treating this aggressive type of breast cancer.
Safety and efficacy of osimertinib plus consolidative stereotactic ablative radiation (SABR) in advanced EGFR mutant non-small cell lung cancer (NSCLC): results from a multi-center Phase II trial
BackgroundDespite high response rates to EGFR inhibitors, patients with advanced EGFR mutant NSCLC generally experience disease progression within two years (osimertinib median PFS 18.9 months, median OS 38.6 months). We sought to determine whether administration of SABR to residual sites…
ARC-9: A randomized study to evaluate etrumadenant based treatment combinations in previously treated metastatic colorectal cancer (mCRC).
For this presentation at ASCO 2024, please email the media contact for more information.
A phase 1 dose expansion study of a first-in-class KAT6 inhibitor (PF-07248144) in patients with advanced or metastatic ER+ HER2− breast cancer.
For this presentation at ASCO 2024, please email the media contact for more information.
ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1/2 study.
For this presentation at ASCO 2024, please email the media contact for more information.
Phase 1/2 trial of the XPO1 inhibitor selinexor in combination with docetaxel in previously treated, advanced KRAS mutant non-small cell lung cancer (NSCLC)
Background: KRAS mutant NSCLC remains a therapeutic challenge. Although KRAS G12C inhibitors are now approved for cases harboring that specific mutation, their efficacy is modest and the G12C variant accounts for only 40% of KRAS mutations in NSCLC. To date,…
Fibrolamellar hepatocellular carcinoma (FL-HCC) epidemiology, survival characteristics, and outcomes: Surveillance, epidemiology, and end results database (SEER) study
Background:Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare and distinctive form of liver cancer that primarily affects adolescents and young adults without underlying liver disease. Unlike conventional HCC, it exhibits unique clinical and histological features and poses a diagnostic and therapeutic…
Association between congenital heart disease and cancer: A meta-analysis of 30 million patients
Background: Birth defects have been associated with increased cancer risk; however, the association between congenital heart disease (CHD) and cancer risk has not been well established with limited and conflicting literature till date. Children afflicted with CHD possess multiple risk factors…
Clinically significant variant classification resulting from the addition of RNA sequencing: Experience at high-volume cancer genetics center
Background: Germline cancer genetic testing plays an important role in prevention, early detection, and targeted therapy1. The increasing use of multi-gene panel testing (MGPT) underscores the importance of accurate variant classification. We report on the significant contribution of RNA analysis…
Cancer screening in sexual and gender minority populations: A systematic review and meta-analysis
Background: The sexual and gender minority (SGM) populations experience a greater cancer burden than their heterosexual or cisgender counterparts. Screening rates for cancer within this cohort are frequently suboptimal, highlighting notable deficiencies in screening recommendations. Inadequate culturally competent care and screening…
Non-Hodgkin lymphoma mortality disparities across different sexes, races, and geographic locations
Background: Non-Hodgkin lymphoma (NHL) is one of the common hematological cancers in the United States (U.S.), accounting for 4% of new cancer cases in 2023. The mortality rate of NHL is the sixth highest among all cancers in the U.S. Our…
A meta-analysis of models for predicting the incidence of brain metastasis in patients with lung cancer
Background: Brain metastasis (BM) represents a significant clinical challenge in the management of lung cancer, impacting patient prognosis and treatment decisions. While various predictive models have been developed to assess the risk of BM development, their performance and applicability remain under…
Evaluating the impact of socioeconomic status on patient satisfaction in radiation oncology
Background: Patient satisfaction (PS) is a critical indicator in evaluating healthcare quality. While the impact of socioeconomic status (SES), on healthcare outcomes is well-documented, its specific connection to PS in the context of radiation oncology remains unclear. This study aims to…
Trilaciclib use for prevention of hematological adverse events in chemotherapy: A meta-analysis of real-world studies and clinical trials
Background: Trilaciclib, a cyclin-dependent kinase (CDK)-4 and -6 inhibitor, is the only FDA-approved agent that preemptively protects hematopoietic stem cells from chemotherapy-induced myelosuppression (CIM) without compromising efficacy. It transiently arrests hematopoietic stem cells in the G1 phase, thus temporarily blocking progression…
The effect of resting dendritic cells on overall survival in the hepatocellular carcinoma tumor microenvironment
Background: Hepatocellular carcinoma (HCC) continues to have a poor prognosis even in the advent of new immunotherapy regimens. An area of growing interest in HCC is its tumor immune microenvironment. Classifying the immune microenvironment based on available genomics can lead to…
Epidemiology, symptomatology, diagnosis and clinical implications of cystic tumors of atrioventricular node (CTAVN): A systematic review
Background: Primary cardiac tumors have an incidence of 0.0017% to 0.03% of all autopsies. CTAVN is a rare tumor associated with sudden cardiac death, and its incidence cannot be accurately determined as the diagnosis has been historically made on incidental or…
Socioeconomic disparities in survival outcomes of patients with SCLC with brain metastases: A nationwide analysis
Background:Despite advances in the management of cancer, socioeconomic disparities have been reported to impact survival outcomes. However, recent state of disparities in SCLC patients with brain metastases (BM) remains unknown. We explored socioeconomic disparities in survival outcomes of SCLC BM…
Trend and burden of cancer related hospitalizations in the US: Insights from a National Inpatient Sample Database analysis
Background: Cancer-related hospitalizations constitute one of the primary drivers of cancer-related healthcare expenses. Understanding the burden and characteristics of these hospitalizations is essential to appropriately direct resources, improve outcomes, and avoid unnecessary hospitalizations. Our study sought to evaluate the national…
Pathways Study Genotype Data, Alliance A011502 Secondary Analysis Headline Roswell Park ASCO24 Presentations
New insights on improving clinical outcomes and quality of life among breast cancer patients highlight the slate of new research presentations Roswell Park Comprehensive Cancer Center experts will deliver at the American Society of Clinical Oncology (ASCO) Annual Meeting at McCormick Place in Chicago next week.
ASCO: Large precision oncology study identifies differences in prostate cancer genomics among a racially and ethnically diverse cohort of U.S. veterans
A new study(Link is external) (Link opens in new window) led by a UCLA-VA collaborative team looking at the landscape of genomic alterations in more than 5,000 veterans with metastatic prostate cancer uncovered differences in the genomic makeup of cancer cells that were associated with race and ethnicity.
Quadruple Therapies and the Future of Multiple Myeloma Treatment
ASCO: Treatment options for multiple myeloma are shifting rapidly, with new patients increasingly being treated with a 4-part drug combination that includes a new immunotherapy agent. What does this mean for patients, and how will treatment change in the future?
Get Ready for ASCO 2024 Annual Meeting
ASCO, the largest event in cancer research, is approaching on May 31st. This year’s meeting promises to be particularly groundbreaking, with new findings and innovations that could revolutionize cancer treatment.